Increased Brain Atrophy Rates in Cognitively Normal Older Adults with Low Cerebrospinal Fluid Aβ1-42

被引:118
作者
Schott, Jonathan M. [1 ]
Bartlett, Jonathan W. [1 ,2 ]
Fox, Nick C. [1 ]
Barnes, Josephine [1 ]
机构
[1] UCL, Inst Neurol, Dementia Res Ctr, London, England
[2] London Sch Hyg & Trop Med, Dept Med Stat, London WC1, England
基金
美国国家卫生研究院;
关键词
PITTSBURGH COMPOUND-B; ALZHEIMERS-DISEASE; BIOMARKER SIGNATURE; IMPAIRMENT; DIAGNOSIS; DEMENTIA; ASSOCIATION; PREVALENCE; MRI;
D O I
10.1002/ana.22315
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To identify cognitively normal individuals at risk of Alzheimer disease (AD) based on cerebrospinal fluid (CSF) A beta 1-42, and to determine rates of cerebral atrophy. Methods: Control subjects from the Alzheimer's Disease Neuroimaging Initiative with CSF and serial magnetic resonance imaging (MRI) were dichotomized on CSF A beta 1-42 (normal control [NC]-high >192pg/ml; NC-low <192pg/ml). Baseline and 1-year MRIs were registered, and brain, hippocampal, and ventricular volumes and annualized volume changes were calculated. Baseline characteristics, CSF profiles, neuropsychology, brain volumes and atrophy rates, and APOE, PICALM, Cl.U, and TOMM40 genotypes were compared. Sample sizes to power presymptomatic clinical trials based on rate of atrophy were calculated. Results: Forty of 105 (38%) were classified as NC-low, and 65 (62%) as NC-high. There were no differences in age (76.3 +/- 5.1 vs 74.9 +/- 5.1 years), gender, brain volumes, and all but 1 cognitive score (Trails B; p = 0.015). The NC-low group had higher tau (p = 0.005) and p-tau (p < 0.001), and was more likely to be APOE4 positive (48% vs 11%, p < 0.001). The NC-low group had significantly higher whole brain loss (9.3 vs 4.4ml/yr, p < 0.001), ventricular expansion (2.04 vs 0.95ml/yr, p = 0.002), and hippocampal atrophy rate (0.07 vs 0.03ml/yr, p = 0.029). Baseline A beta 1-42 level was strongly correlated with rate of brain atrophy only in the NC-low group (p < 0.001). Using 141 (95% confidence interval, 86-287) patients per arm provides 80% power in a 1-year treatment trial to show 25% slowing of brain atrophy in the NC-low group. Interpretation: A significant percentage of healthy older adults have CSF profiles consistent with AD and increased rates of brain atrophy, suggesting that they may be in the earliest stages of neurodegeneration. Brain atrophy may be a feasible outcome measure for AD prevention studies. ANN NEUROL 2010;68:825-834
引用
收藏
页码:825 / 834
页数:10
相关论文
共 36 条
  • [1] [Anonymous], Changing the Trajectory of Alzheimer's Disease: How a Treatment by 2025 Saves Lives and Dollars
  • [2] Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
    Bertram, Lars
    McQueen, Matthew B.
    Mullin, Kristina
    Blacker, Deborah
    Tanzi, Rudolph E.
    [J]. NATURE GENETICS, 2007, 39 (01) : 17 - 23
  • [3] NEUROPATHOLOGICAL STAGING OF ALZHEIMER-RELATED CHANGES
    BRAAK, H
    BRAAK, E
    [J]. ACTA NEUROPATHOLOGICA, 1991, 82 (04) : 239 - 259
  • [4] Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: Findings from the Alzheimer's Disease Neuroimaging Initiative
    Chen, Kewei
    Langbaum, Jessica B. S.
    Fleisher, Adam S.
    Ayutyanont, Napatkamon
    Reschke, Cole
    Lee, Wendy
    Liu, Xiaofen
    Bandy, Dan
    Alexander, Gene E.
    Thompson, Paul M.
    Foster, Norman L.
    Harvey, Danielle J.
    de Leon, Mony J.
    Koeppe, Robert A.
    Jagust, William J.
    Weiner, Michael W.
    Reiman, Eric M.
    [J]. NEUROIMAGE, 2010, 51 (02) : 654 - 664
  • [5] Larger temporal volume in elderly with high versus low beta-amyloid deposition
    Chetelat, Gael
    Villemagne, Victor L.
    Pike, Kerryn E.
    Baron, Jean-Claude
    Bourgeat, Pierrick
    Jones, Gareth
    Faux, Noel G.
    Ellis, Kathryn A.
    Salvado, Olivier
    Szoeke, Cassandra
    Martins, Ralph N.
    Ames, David
    Masters, Colin L.
    Rowe, Christopher C.
    [J]. BRAIN, 2010, 133 : 3349 - 3358
  • [6] Integrating ADNI results into Alzheimer's disease drug development programs
    Cummings, Jeffrey L.
    [J]. NEUROBIOLOGY OF AGING, 2010, 31 (08) : 1481 - 1492
  • [7] Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People
    De Meyer, Geert
    Shapiro, Fred
    Vanderstichele, Hugo
    Vanmechelen, Eugeen
    Engelborghs, Sebastiaan
    De Deyn, Peter Paul
    Coart, Els
    Hansson, Oskar
    Minthon, Lennart
    Zetterberg, Henrik
    Blennow, Kaj
    Shaw, Leslie
    Trojanowski, John Q.
    [J]. ARCHIVES OF NEUROLOGY, 2010, 67 (08) : 949 - 956
  • [8] Research criteria for the diagnosis of Alzheimer"s disease: revising the NINCDS-ADRDA criteria
    Dubois, Bruno
    Feldman, Howard H.
    Jacova, Claudia
    Dekosky, Steven T.
    Barberger-Gateau, Pascale
    Cummings, Jeffrey
    Delocourte, Andre
    Galasko, Douglas
    Gauthier, Serge
    Jicha, Gregory
    Meguro, Kenichi
    O'Brien, John
    Pasquier, Florence
    Robert, Philippe
    Rossor, Martin
    Solloway, Steven
    Stern, Yaakov
    Visser, Pieter J.
    Scheltens, Philip
    [J]. LANCET NEUROLOGY, 2007, 6 (08) : 734 - 746
  • [9] Decreased Cerebrospinal Fluid Aβ42 Correlates with Brain Atrophy in Cognitively Normal Elderly
    Fagan, Anne M.
    Head, Denise
    Shah, Aarti R.
    Marcus, Daniel
    Mintun, Mark
    Morris, John C.
    Holtzman, David M.
    [J]. ANNALS OF NEUROLOGY, 2009, 65 (02) : 176 - 183
  • [10] Global prevalence of dementia: a Delphi consensus study
    Ferri, CP
    Prince, M
    Brayne, C
    Brodaty, H
    Fratiglioni, L
    Ganguli, M
    Hall, K
    Hasegawa, K
    Hendrie, H
    Huang, YQ
    Jorm, A
    Mathers, C
    Menezes, PR
    Rimmer, E
    Scazufca, M
    [J]. LANCET, 2005, 366 (9503) : 2112 - 2117